April 10, 2008
LA JOLLA, Calif.—Methylsulfonylmethane (MSM) may help stymie osteoarthritis (OA) progression, according to a new animal study (FASEB J. 2008;22:1094.3). The right knee ACL of mature NZW rabbits (n=10) was transected. Five weeks after the surgery, a delivery system for MSM (as OptiMSM®, from Bergstrom Nutrition) or a placebo was implanted in the joint. Nine weeks after surgery, OA grades of the femoral surface were: Grade I intact surface, Grade II minimal fibrillation, Grade III overt fibrillation, and Grade IV erosion of the articular cartilage surface. The results showed two Grade III and one Grade IV (avg. 3.3) in the control group. The MSM-treated group showed one Grade I, three Grade II, one Grade III and two Grade IV (avg. 2.6). Expression of type II collagen and aggrecan on cartilage showed no difference between control and experimental groups; however, the inflammation level in both cartilage and synovial tissue was decreased (P<.01). Researchers concluded MSM therapy is a potential application for non-invasive treatment of OA joints.
“We are pleased with these findings, which reinforce our commitment to sponsoring both pre-clinical and clinical research,” said Tony Keller, president of Bergstrom Nutrition, the manufacturers and marketers of OptiMSM and sponsor of the study. “Our clinical research program for 2008-2009 will expand upon [this] work and prior clinical trials we have sponsored. We will also be exploring innovative directions that will illuminate new uses for OptiMSM.”
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023